1. Screening Libraries
  2. MAPK Compound Library

MAPK Compound Library

Cat. No.: HY-L010
Library Contents: XLSX PDF

A unique collection of 114 MAPK signaling inhibitors for high throughput screening (HTS) and high content screening (HCS).

MAPK Compound Library
Size (Pre-dissolved DMSO or Solid) Price Stock
30 μL/well (10 mM solution) Get quote In-stock
50 μL/well (10 mM solution) Get quote In-stock
100 μL/well (10 mM solution) Get quote In-stock
250 μL/well (10 mM solution) Get quote In-stock

Please contact us at

[email protected]

Top Publications Citing Use of Products
  • Description

  • Product Details

  • Composition

  • Contents

  • Documentation

Description
& Advantages

•   A unique collection of 114 MAPK signaling inhibitors for high throughput screening (HTS) and high content screening (HCS).

•   Targets such as ERK, JNK, MEK, p38 MAPK, Raf, RSK, etc.

•   A useful tool for MAPK-related drug discovery and disease research.

•   Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.

•   Structurally diverse, medicinally active, and cell permeable.

•   More detailed compound information with structure, IC50, and brief introduction.

•   NMR and HPLC validated to ensure high purity and quality.

•   All compounds are in stock and continuously updated.

Product Details
Formulation:
A collection of 114 MAPK/ERK signaling related compounds supplied as pre-dissolved DMSO solutions or Solid
Container:
96 Well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
Storage:
-80°C
Shipping:
Blue ice
Composition

MAPK Compound Library

Source: MedChem Express

Contents of MAPK Compound Library

Plate layout: HY-L010-1

1 2 3 4 5 6 7 8 9 10 11 12
a Empty TA-01 IQ-1 RAF709 (E)-Necrosulfonamide APS-2-79 NCB-0846 Sorafenib Sorafenib (Tosylate) BRAF inhibitor RAF265 Empty
b Empty PD0325901 SB 203580 SB 202190 Doramapimod Neflamapimod Regorafenib Regorafenib (monohydrate) BI-78D3 VX-702 Losmapimod Empty
c Empty PH-797804 Talmapimod TAK-715 BI-D1870 CGP 57380 GW 5074 PD 169316 Pluripotin AG126 SB-590885 Empty
d Empty Trametinib Trametinib (DMSO solvate) AZ 628 SB 239063 SLV-2436 ETC-206 PD98059 U0126 SP600125 Pimasertib Empty
e Empty BIX02188 BIX02189 Vemurafenib AZD8330 AT7867 AT7867 (dihydrochloride) PD318088 FR 180204 LY-2584702 (tosylate salt) SKF-86002 Empty
f Empty LY3009120 URMC-099 L-779450 MK2-IN-1 (hydrochloride) CCT196969 CC-401 (hydrochloride) Cobimetinib Cobimetinib (hemifumarate) Ralimetinib dimesylate Regorafenib (Hydrochloride) Empty
g Empty JNK-IN-8 ZM 336372 TAK-733 B-Raf inhibitor 1 VX-11e XMD8-92 Dabrafenib Dabrafenib (Mesylate) Refametinib Bentamapimod Empty
h Empty Agerafenib Binimetinib TAK-580 SL327 GDC-0623 TIC10 XMD17-109 TAK-632 PF-4708671 Ulixertinib Empty

Plate layout: HY-L010-2

1 2 3 4 5 6 7 8 9 10 11 12
a Empty TCS JNK 5a AT13148 APTO-253 Acumapimod Pexmetinib Ro 5126766 Selonsertib BI-847325 PLX8394 PF-06260933 Empty
b Empty NQDI-1 Tauroursodeoxycholate (Sodium) trans-Zeatin LJH685 LJI308 ML264 CI-1040 Selumetinib GDC-0879 PLX-4720 Empty
c Empty Methylthiouracil Honokiol Ginsenoside Re Bakuchiol Pachymic acid Quercitrin Astragaloside IV Corynoxeine Carnosol Dehydrocorydaline (chloride) Empty
d Empty Isovitexin Isorhamnetin Magnolin Loureirin B Empty Empty Empty Empty Empty Empty Empty
e Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty
f Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty
g Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty
h Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty
Documentation

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
MAPK Compound Library
Cat. No.:
HY-L010
Quantity:

Request SDF File

Please enter your email address. We will send your requested SDF file to you as soon as possible.